US › Healthcare

Rani Therapeutics Holdings Inc (RANI)

US · Healthcare · Biotechnology

$0.55+5.93%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$1.7M

Net profit

$-7.4M

EPS

$-0.04

EPS estimate

$-0.05

Net margin

-432.7%

EPS came in at -0.04 against a street estimate of -0.05 — a beat of 20.0%.

Key statistics

Market cap

$72.5M

Forward P/E

0.0

P/B

1.63

Book value

$0.35

EPS (TTM)

$-0.13

52-week high

$2.15

52-week low

$0.51

50-day MA

$0.75

200-day MA

$0.92

Beta

0.68

Analyst view

Analysts rate Rani Therapeutics Holdings Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.20.

Shareholding

Insiders

4.92%

Institutions

46.86%

Largest institutional holders

Fund	Stake
Samsara BioCapital, LLC	8.98%
RA Capital Management, LLC	7.36%
Awm Investment Company Inc	6.50%
Vanguard Capital Management, LLC	3.95%
Longaeva Partners L.P.	2.02%
Polar Asset Management Partners	2.01%
Siren, L.L.C.	1.73%
Heights Capital Management Inc	0.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rani Therapeutics Holdings Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.